Abstract 3944
Background
We initially ascertained the value of inflammatory indexes in predicting severe acute radiation pneumonitis (SARP). Furthermore, we firstly built a novel nomogram and risk classification system integrating clinicopathological, dosimetric and biological parameters to individually and precisely identify SARP in patients with esophageal cancer (EC) who received radiotherapy (RT).
Methods
All data were collected from 312 EC patients. Logistic regression was used to choose predictors of SARP and then build nomogram. The validation of nomogram was performed by area under the ROC curve (AUC), calibration curves and decision curve analyses (DCA). A risk classification system was generated by recursive partitioning analysis (RPA).
Results
The Subjective Global Assessment (SGA) score, pulmonary fibrosis score (PFS), planning target volume/total lungs volume (PTV/LV), mean lung dose (MLD) and systemic immuneinflammation index (SII) were independent predictors of SARP and finally incorporated into the nomogram. The AUC of nomogram for SARP prediction was 0.852, which was much higher than any other factor (range, 0.604-0.712). Calibration curves indicated favorable consistency between the nomogram prediction and the actual outcomes. DCA exhibited satisfactory clinical utility. A risk classification system was built to perfectly divide patients into three risk groups which were low-risk group (7.1%, score 0–158), intermediate-risk group (38%, score 159–280), and high-risk group (71.4%, score>280).
Conclusions
SGA score, PFS, PTV/LV, MLD and SII were potential valuable markers in predicting SARP. The constructed nomogram and corresponding risk classification system with superior prediction ability for SARP could assist in patients counseling and guide treatment decision making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3278 - Immune-Related Gene Expression Profiling after Neoadjuvant Chemotherapy (NACT) of Ovarian High-Grade Serous Carcinoma
Presenter: Luis Manso
Session: Poster Display session 2
Resources:
Abstract
4906 - Tumor-infiltrating lymphocytes (TILs) in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy: A restrospective study
Presenter: Sara Giovannoni
Session: Poster Display session 2
Resources:
Abstract
3919 - Prognostic significance of elements of the adaptive immunity in the microenvironment of epithelial ovarian cancer.
Presenter: Periklis Foukas
Session: Poster Display session 2
Resources:
Abstract
5139 - Neutrophil-to-lymphocyte ratio predicts platinum sensitivity in epithelial ovarian cancer patients: a MITO24 retrospective study
Presenter: Alberto Farolfi
Session: Poster Display session 2
Resources:
Abstract
4212 - The prognostic impact of monocyte to lymphocyte ratio (MLR) in advanced epithelial ovarian cancer (EOC)
Presenter: Marc Cucurull Salamero
Session: Poster Display session 2
Resources:
Abstract
5123 - TP53 Hotspot mutations as immunoreactive neoantigens define a signature with differential survival outcomes in advanced ovarian cancer
Presenter: Marica Garziera
Session: Poster Display session 2
Resources:
Abstract
3795 - Use of bevacizumab (Bev) in real life for first-line (fl) treatment of ovarian cancer (OC)/ The GINECO ENCOURAGE cohort of 500 French patients
Presenter: Dominique Berton-Rigaud
Session: Poster Display session 2
Resources:
Abstract
2359 - Phase II study: Letrozole maintenance therapy after first line chemotherapy in patients with advanced serous and endometrioid ovarian cancer
Presenter: Alexandra Tyulyandina
Session: Poster Display session 2
Resources:
Abstract
3619 - Baseline IPI (Immune Prognostic Index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI).
Presenter: Felix Blanc-Durand
Session: Poster Display session 2
Resources:
Abstract
3474 - Preselecting tumor-infiltrating lymphocyte subsets to implement adoptive inmmunotherapy in ovarian cancer
Presenter: Diego Salas-Benito
Session: Poster Display session 2
Resources:
Abstract